ADMA Biologics (ADMA) Financials

$22.15 +1.24 (+5.93%)

Closing price 04:00 PM Eastern

Extended Trading

$21.86 -0.29 (-1.29%)

As of 07:54 PM Eastern

Annual Income Statements for ADMA Biologics

This table shows ADMA Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-18	-20	-44	-66	-48	-76	-72	-66	-28	198
Consolidated Net Income / (Loss)	-18	-20	-44	-66	-48	-76	-72	-66	-28	198
Net Income / (Loss) Continuing Operations	-18	-20	-44	-66	-48	-76	-72	-66	-28	198
Total Pre-Tax Income	-18	-20	-44	-66	-48	-76	-72	-66	-28	126
Total Operating Income	-16	-17	-39	-60	-41	-65	-58	-39	22	139
Total Gross Profit	2.87	4.30	-6.40	-25	-10	-19	1.17	35	89	220
Total Revenue	7.18	11	23	17	29	42	81	154	258	426
Operating Revenue	7.18	11	23	17	29	42	81	154	258	426
Total Cost of Revenue	4.31	6.36	29	42	40	61	80	119	169	207
Operating Cost of Revenue	4.31	6.36	29	42	40	61	80	119	169	207
Total Operating Expenses	18	22	33	35	31	46	60	75	67	81
Selling, General & Admin Expense	11	14	25	30	28	39	55	70	63	78
Research & Development Expense	7.02	7.69	5.57	3.93	2.34	5.91	3.65	3.61	3.30	1.81
Amortization Expense	-	0.00	1.23	0.84	0.84	0.72	0.72	0.72	0.72	0.39
Total Other Income / (Expense), net	-2.46	-2.18	-4.45	-5.45	-6.85	-11	-13	-27	-50	-13
Interest Expense	2.56	2.24	4.50	5.52	19	11	13	26	51	15
Interest & Investment Income	0.04	0.05	0.06	0.20	0.80	0.29	0.04	0.05	1.62	2.10
Other Income / (Expense), net	0.07	0.00	-0.01	-0.13	11	-0.13	-0.25	-0.64	-0.29	-0.19
Income Tax Expense	-	-	-	-	-	-	-	0.00	0.00	-72
Basic Earnings per Share	($1.73)	($1.61)	($1.91)	($1.45)	($0.89)	($0.88)	($0.51)	($0.33)	($0.13)	$0.85
Weighted Average Basic Shares Outstanding	10.41M	12.15M	22.90M	45.19M	54.35M	86.15M	139.58M	197.87M	223.98M	233.08M
Diluted Earnings per Share	($1.73)	($1.61)	($1.91)	($1.45)	($0.89)	($0.88)	($0.51)	($0.33)	($0.13)	$0.81
Weighted Average Diluted Shares Outstanding	10.41M	12.15M	22.90M	45.19M	54.35M	86.15M	139.58M	197.87M	223.98M	243.34M
Weighted Average Basic & Diluted Shares Outstanding	10.41M	12.15M	22.90M	45.19M	54.35M	86.15M	195.92M	222.16M	228.22M	237.62M

This table shows ADMA Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-15	-12	-6.79	-6.37	2.57	-18	18	32	36	112
Consolidated Net Income / (Loss)	-15	-12	-6.79	-6.37	2.57	-18	18	32	36	112
Net Income / (Loss) Continuing Operations	-15	-12	-6.79	-6.37	2.57	-18	18	32	36	112
Total Pre-Tax Income	-15	-12	-6.79	-6.37	2.57	-18	18	36	37	35
Total Operating Income	-9.32	-6.06	-0.81	-0.47	8.69	14	22	39	40	38
Total Gross Profit	9.66	14	17	17	25	31	39	57	60	63
Total Revenue	41	50	57	60	67	74	82	107	120	118
Operating Revenue	41	50	57	60	67	74	82	107	120	118
Total Cost of Revenue	31	36	40	43	43	43	43	50	60	54
Operating Cost of Revenue	31	36	40	43	43	43	43	50	60	54
Total Operating Expenses	19	20	17	17	16	17	17	18	20	25
Selling, General & Admin Expense	18	19	16	16	15	16	17	18	20	25
Research & Development Expense	1.04	1.07	0.86	1.40	0.60	0.45	0.45	0.56	0.41	0.39
Amortization Expense	0.18	0.18	0.18	0.18	0.18	0.19	0.19	0.14	0.03	0.03
Total Other Income / (Expense), net	-5.58	-6.17	-5.98	-5.90	-6.12	-32	-3.42	-3.35	-2.89	-3.61
Interest Expense	5.58	5.74	6.12	6.30	6.40	32	3.77	3.78	3.50	4.12
Interest & Investment Income	0.01	0.00	0.17	0.41	0.42	0.61	0.38	0.45	0.67	0.60
Other Income / (Expense), net	-0.01	-0.44	-0.03	-0.01	-0.15	-0.10	-0.04	-0.02	-0.06	-0.09
Income Tax Expense	-	-	0.00	0.00	0.00	-	0.60	3.79	0.84	-77
Basic Earnings per Share	($0.08)	($0.05)	($0.03)	($0.03)	$0.01	($0.08)	$0.08	$0.14	$0.15	$0.48
Weighted Average Basic Shares Outstanding	196.38M	197.87M	221.92M	222.68M	225.28M	223.98M	228.87M	232.42M	234.57M	233.08M
Diluted Earnings per Share	($0.08)	($0.05)	($0.03)	($0.03)	$0.01	($0.08)	$0.08	$0.13	$0.15	$0.45
Weighted Average Diluted Shares Outstanding	196.38M	197.87M	221.92M	222.68M	233.76M	223.98M	236.41M	242.17M	244.80M	243.34M
Weighted Average Basic & Diluted Shares Outstanding	196.78M	222.16M	222.27M	224.91M	225.97M	228.22M	231.81M	233.08M	236.39M	237.62M

This table details how cash moves in and out of ADMA Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-6.76	-0.53	39	-22	-0.00	29	-4.83	35	-35	52
Net Cash From Operating Activities	-15	-18	-37	-63	-76	-102	-112	-60	8.80	119
Net Cash From Continuing Operating Activities	-15	-18	-37	-63	9.71	-102	-112	-60	8.80	119
Net Income / (Loss) Continuing Operations	-18	-20	-44	-66	-48	-76	-72	-66	-28	198
Consolidated Net Income / (Loss)	-18	-20	-44	-66	-48	-76	-72	-66	-28	198
Depreciation Expense	0.47	0.47	2.69	3.45	3.26	3.94	5.50	7.11	8.33	8.05
Amortization Expense	0.27	0.53	0.64	0.96	1.04	1.64	1.75	2.26	2.45	0.81
Non-Cash Adjustments To Reconcile Net Income	2.55	1.25	3.44	2.35	12	1.95	3.71	15	36	15
Changes in Operating Assets and Liabilities, net	-0.74	-1.01	-0.28	-3.69	41	-34	-52	-18	-10	-103
Net Cash From Investing Activities	-1.74	0.90	15	-2.10	-3.81	-13	-14	-14	-4.98	-8.58
Net Cash From Continuing Investing Activities	-1.74	0.90	15	-2.10	-3.81	-13	-14	-14	-4.98	-8.58
Purchase of Property, Plant & Equipment	-0.03	-0.07	-2.68	-2.10	-3.81	-13	-14	-14	-4.77	-8.23
Acquisitions	-	0.00	-	-	-	-	0.00	0.00	-0.21	-0.35
Net Cash From Financing Activities	10	17	61	43	80	144	121	109	-39	-58
Net Cash From Continuing Financing Activities	10	17	61	43	80	144	121	109	-39	-58
Repayment of Debt	-16	-0.06	-22	0.00	-32	-15	0.00	-105	-172	-60
Issuance of Debt	-	4.00	45	0.04	73	28	0.00	152	135	0.00
Issuance of Common Equity	10	13	39	43	48	131	121	65	0.00	0.00
Other Financing Activities, net	16	0.00	-1.78	0.01	-9.21	-0.02	-0.10	-2.76	-1.91	2.15

This table details how cash moves in and out of ADMA Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-18	52	-17	-6.69	12	-23	-6.03	43	-1.54	16
Net Cash From Operating Activities	-13	-7.38	-15	-6.06	12	18	-2.22	46	25	50
Net Cash From Continuing Operating Activities	-13	-7.38	-15	-6.06	12	18	-2.22	46	25	50
Net Income / (Loss) Continuing Operations	-15	-12	-6.79	-6.37	2.57	-18	18	32	36	112
Consolidated Net Income / (Loss)	-15	-12	-6.79	-6.37	2.57	-18	18	32	36	112
Depreciation Expense	1.86	1.94	2.03	2.10	2.09	2.11	2.11	2.05	1.94	1.94
Amortization Expense	0.95	0.46	0.45	0.65	0.69	0.66	0.22	0.19	0.22	0.18
Non-Cash Adjustments To Reconcile Net Income	2.30	2.46	2.11	2.62	2.78	29	2.16	2.86	3.19	6.75
Changes in Operating Assets and Liabilities, net	-3.49	-0.00	-13	-5.06	3.86	3.60	-25	8.48	-16	-71
Net Cash From Investing Activities	-3.38	-3.75	-1.95	-0.87	-0.76	-1.41	-2.36	-2.37	-1.10	-2.75
Net Cash From Continuing Investing Activities	-3.38	-3.75	-1.95	-0.87	-0.76	-1.41	-2.36	-2.37	-1.10	-2.75
Purchase of Property, Plant & Equipment	-3.38	-3.75	-1.95	-0.87	-0.76	-1.20	-2.35	-2.07	-1.06	-2.76
Acquisitions	-	-	0.00	-	-	-0.21	-0.02	-0.30	-0.04	0.01
Net Cash From Financing Activities	-0.84	63	-0.65	0.24	0.42	-39	-1.45	-0.36	-25	-31
Net Cash From Continuing Financing Activities	-0.84	63	-0.65	0.24	0.42	-39	-1.45	-0.36	-25	-31
Repayment of Debt	-0.40	-0.00	-	-	-	-172	-	-	-	-30
Other Financing Activities, net	-0.44	-1.90	-0.65	0.24	0.42	-1.92	-1.45	-0.36	4.53	-0.58

This table presents ADMA Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	24	24	108	89	127	208	276	348	329	489
Total Current Assets	21	22	62	45	86	154	209	270	257	331
Cash & Equivalents	10	9.91	43	23	27	56	51	87	51	103
Accounts Receivable	0.92	1.02	3.88	1.39	3.47	13	29	16	27	50
Inventories, net	3.45	5.02	13	19	53	82	125	163	173	170
Prepaid Expenses	0.11	0.31	1.23	1.77	2.53	3.05	4.34	5.10	5.33	8.03
Plant, Property, & Equipment, net	2.40	2.00	30	30	32	42	51	58	54	55
Total Noncurrent Assets	0.03	0.03	15	14	9.53	12	17	20	18	103
Goodwill	-	0.00	3.53	3.53	3.53	3.53	3.53	3.53	3.53	3.53
Intangible Assets	-	0.00	4.85	4.00	3.16	2.44	1.73	1.01	0.50	0.46
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	-	-	0.00	84
Other Noncurrent Operating Assets	0.03	0.03	6.83	6.70	2.84	6.37	11	15	14	14
Total Liabilities & Shareholders' Equity	24	24	108	89	127	208	276	348	329	489
Total Liabilities	23	28	68	69	101	119	135	196	194	140
Total Current Liabilities	4.22	11	9.44	9.63	14	20	30	39	50	56
Accounts Payable	2.09	2.56	5.92	5.90	9.17	11	12	13	16	20
Accrued Expenses	1.97	2.39	3.38	3.55	4.48	8.37	17	25	33	34
Current Deferred Revenue	0.15	0.15	0.14	0.14	0.14	0.14	0.14	0.14	0.18	0.14
Other Current Liabilities	-	0.02	-	-	0.23	0.37	0.59	0.91	1.05	1.22
Total Noncurrent Liabilities	19	17	58	59	87	99	105	157	144	84
Long-Term Debt	14	14	43	44	83	93	95	143	131	72
Capital Lease Obligations	0.04	-	0.00	0.12	1.30	4.33	7.46	11	9.78	8.56
Noncurrent Deferred Revenue	2.96	2.69	2.55	2.40	2.26	2.12	1.98	1.83	1.69	1.55
Other Noncurrent Operating Liabilities	1.43	0.12	13	13	0.11	0.05	0.40	1.85	2.11	1.67
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.82	-4.46	40	20	26	88	141	152	135	349
Total Preferred & Common Equity	0.82	-4.46	40	20	26	88	141	152	135	349
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	0.82	-4.46	40	20	26	88	141	152	135	349
Common Stock	88	102	191	236	291	429	553	630	641	658
Retained Earnings	-87	-107	-151	-216	-265	-340	-412	-478	-506	-309

This table presents ADMA Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	301	341	343	349	351	376	391
Total Current Assets	224	264	266	274	276	304	318
Cash & Equivalents	35	69	63	74	45	88	87
Accounts Receivable	21	27	37	31	50	30	50
Inventories, net	163	164	162	163	178	180	172
Prepaid Expenses	5.37	4.38	5.22	5.11	3.74	5.52	9.55
Plant, Property, & Equipment, net	57	57	56	55	55	54	54
Total Noncurrent Assets	20	19	20	20	19	18	19
Goodwill	3.53	3.53	3.53	3.53	3.53	3.53	3.53
Intangible Assets	1.19	0.83	0.66	0.48	0.32	0.48	0.49
Other Noncurrent Operating Assets	15	15	16	16	15	14	15
Total Liabilities & Shareholders' Equity	301	341	343	349	351	376	391
Total Liabilities	200	195	196	198	197	188	159
Total Current Liabilities	44	37	42	42	53	44	45
Accounts Payable	25	13	12	11	17	14	16
Accrued Expenses	18	23	29	30	34	28	28
Current Deferred Revenue	0.14	0.14	0.14	0.14	1.12	1.13	0.14
Other Current Liabilities	0.72	0.96	0.98	0.98	1.09	1.14	1.19
Total Noncurrent Liabilities	156	158	154	156	144	144	114
Long-Term Debt	141	144	140	142	131	131	101
Capital Lease Obligations	11	10	10	9.97	9.49	9.18	8.87
Noncurrent Deferred Revenue	1.87	1.80	1.76	1.73	1.65	1.62	1.58
Other Noncurrent Operating Liabilities	1.86	1.84	2.02	2.00	2.09	2.08	2.06
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	100	146	147	151	154	188	232
Total Preferred & Common Equity	100	146	147	151	154	188	232
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	100	146	147	151	154	188	232
Common Stock	566	630	638	640	642	645	652
Retained Earnings	-466	-485	-491	-489	-488	-456	-420

This table displays calculated financial ratios and metrics derived from ADMA Biologics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.34%	48.53%	113.49%	-25.37%	72.79%	43.85%	91.72%	90.36%	67.59%	65.15%
EBITDA Growth	6.08%	-10.96%	-120.49%	-55.63%	53.88%	-130.22%	13.60%	40.38%	204.90%	359.55%
EBIT Growth	4.02%	-12.17%	-126.94%	-53.65%	50.14%	-115.92%	9.87%	31.77%	153.36%	550.22%
NOPAT Growth	3.15%	-11.71%	-126.83%	-53.37%	31.29%	-56.71%	10.08%	32.56%	154.95%	1,343.21%
Net Income Growth	-6.88%	-8.60%	-124.23%	-50.24%	26.56%	-56.90%	5.41%	8.02%	57.15%	800.00%
EPS Growth	4.42%	6.94%	-18.63%	24.08%	38.62%	1.12%	42.05%	35.29%	60.61%	723.08%
Operating Cash Flow Growth	-4.85%	-18.49%	-104.02%	-68.17%	-21.56%	-33.87%	-10.16%	47.04%	114.79%	1,248.55%
Free Cash Flow Firm Growth	18.72%	-39.00%	-360.41%	31.95%	-60.24%	-27.10%	-13.73%	47.77%	118.30%	1,071.15%
Invested Capital Growth	-53.06%	127.25%	8,304.18%	6.57%	103.55%	54.43%	48.43%	13.81%	2.39%	45.73%
Revenue Q/Q Growth	171.82%	2.61%	0.12%	-31.87%	37.35%	4.76%	18.14%	18.09%	10.21%	11.40%
EBITDA Q/Q Growth	28.54%	14.20%	-62.80%	-13.30%	25.24%	-17.64%	7.76%	19.14%	188.84%	18.89%
EBIT Q/Q Growth	27.41%	13.11%	-63.41%	-11.24%	22.31%	-16.68%	6.35%	14.60%	2,879.15%	21.02%
NOPAT Q/Q Growth	27.22%	13.09%	-63.37%	-11.06%	17.39%	-16.92%	6.46%	15.34%	1,513.68%	90.21%
Net Income Q/Q Growth	22.46%	11.14%	-63.97%	-8.33%	13.41%	-13.22%	3.71%	6.28%	-23.71%	190.13%
EPS Q/Q Growth	-3.59%	5.85%	4.02%	-9.02%	19.09%	-3.53%	20.31%	5.71%	-30.00%	189.29%
Operating Cash Flow Q/Q Growth	-8.26%	2.48%	-35.40%	-9.49%	-1.14%	-14.05%	-1.12%	30.48%	154.40%	37.91%
Free Cash Flow Firm Q/Q Growth	27.08%	4.85%	-36.42%	-5.97%	1.46%	-16.37%	-9.64%	37.99%	191.26%	30.64%
Invested Capital Q/Q Growth	9.01%	157.13%	26.66%	18.59%	15.88%	15.87%	18.24%	0.69%	-2.20%	27.96%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	39.93%	40.34%	-28.14%	-148.42%	-34.60%	-45.17%	1.45%	22.89%	34.44%	51.48%
EBITDA Margin	-204.94%	-153.10%	-158.12%	-329.75%	-88.00%	-140.84%	-63.47%	-19.88%	12.44%	34.62%
Operating Margin	-216.14%	-162.56%	-172.71%	-354.95%	-141.14%	-153.75%	-72.12%	-25.55%	8.38%	32.59%
EBIT Margin	-215.20%	-162.52%	-172.76%	-355.70%	-102.64%	-154.06%	-72.43%	-25.96%	8.27%	32.55%
Profit (Net Income) Margin	-250.36%	-183.05%	-192.26%	-387.06%	-164.50%	-179.41%	-88.52%	-42.77%	-10.94%	46.35%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	157.24%
Interest Burden Percent	116.34%	112.64%	111.29%	108.82%	160.27%	116.46%	122.21%	164.76%	-132.30%	90.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-57.24%
Return on Invested Capital (ROIC)	0.00%	0.00%	-140.55%	-105.59%	-46.33%	-42.55%	-25.38%	-13.40%	6.83%	79.32%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-1,130.62%	-342.99%	-95.01%	-103.70%	-91.85%	-78.25%	-48.77%	16.83%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	-103.40%	-113.18%	-163.75%	-89.83%	-37.08%	-31.57%	-26.50%	2.32%
Return on Equity (ROE)	-526.23%	1,073.36%	-243.95%	-218.77%	-210.08%	-132.38%	-62.46%	-44.96%	-19.67%	81.65%
Cash Return on Invested Capital (CROIC)	0.00%	-3,101.67%	-335.85%	-111.95%	-114.55%	-85.34%	-64.37%	-26.32%	4.47%	42.10%
Operating Return on Assets (OROA)	-60.89%	-73.11%	-59.71%	-61.37%	-27.90%	-38.86%	-24.23%	-12.81%	6.30%	33.94%
Return on Assets (ROA)	-70.83%	-82.34%	-66.45%	-66.78%	-44.71%	-45.25%	-29.61%	-21.10%	-8.33%	48.34%
Return on Common Equity (ROCE)	-526.23%	1,073.36%	-243.94%	-218.77%	-210.08%	-132.38%	-62.46%	-44.96%	-19.67%	81.65%
Return on Equity Simple (ROE_SIMPLE)	-2,188.85%	437.83%	-108.49%	-332.53%	-184.32%	-85.83%	-50.75%	-43.37%	-20.89%	56.64%
Net Operating Profit after Tax (NOPAT)	-11	-12	-28	-42	-29	-45	-41	-28	15	219
NOPAT Margin	-151.30%	-113.79%	-120.90%	-248.46%	-98.80%	-107.63%	-50.48%	-17.88%	5.86%	51.25%
Net Nonoperating Expense Percent (NNEP)	-147.78%	613.49%	990.07%	237.40%	48.68%	61.15%	66.48%	64.86%	55.60%	62.49%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-9.02%	5.49%	50.83%
Cost of Revenue to Revenue	60.07%	59.66%	128.14%	248.42%	134.60%	145.17%	98.55%	77.11%	65.56%	48.52%
SG&A Expenses to Revenue	158.33%	130.78%	110.96%	178.44%	95.68%	92.90%	68.18%	45.63%	24.51%	18.38%
R&D to Revenue	97.75%	72.12%	24.47%	23.11%	7.99%	13.99%	4.50%	2.35%	1.28%	0.43%
Operating Expenses to Revenue	256.07%	202.89%	144.58%	206.53%	106.54%	108.58%	73.57%	48.44%	26.07%	18.89%
Earnings before Interest and Taxes (EBIT)	-15	-17	-39	-60	-30	-65	-59	-40	21	139
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-15	-16	-36	-56	-26	-59	-51	-31	32	148
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	105.31	0.00	2.05	5.60	9.06	2.09	1.96	5.02	7.55	11.62
Price to Tangible Book Value (P/TBV)	105.31	0.00	2.59	9.05	12.17	2.24	2.03	5.18	7.79	11.75
Price to Revenue (P/Rev)	12.05	6.19	3.64	6.52	8.08	4.37	3.41	4.96	3.96	9.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.51
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.88%
Enterprise Value to Invested Capital (EV/IC)	0.00	153.98	2.10	3.21	3.51	1.74	1.70	3.79	4.95	12.34
Enterprise Value to Revenue (EV/Rev)	11.70	6.65	3.57	7.79	10.05	5.35	4.04	5.39	4.30	9.45
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	34.56	27.31
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	52.02	29.05
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	73.33	18.45
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	126.18	33.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	112.11	34.76
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	17.42	-4.54	1.07	2.24	3.23	1.10	0.72	1.01	1.04	0.23
Long-Term Debt to Equity	17.40	-3.17	1.07	2.24	3.23	1.10	0.72	1.01	1.04	0.23
Financial Leverage	-1.41	-0.66	0.09	0.33	1.72	0.87	0.40	0.40	0.54	0.14
Leverage Ratio	7.43	-13.04	3.67	3.28	4.70	2.93	2.11	2.13	2.36	1.69
Compound Leverage Factor	8.64	-14.68	4.09	3.56	7.53	3.41	2.58	3.51	-3.12	1.53
Debt to Total Capital	94.57%	128.27%	51.58%	69.11%	76.34%	52.44%	42.02%	50.26%	50.94%	18.82%
Short-Term Debt to Total Capital	0.10%	38.76%	0.00%	0.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	94.47%	89.51%	51.58%	69.06%	76.34%	52.44%	42.02%	50.26%	50.94%	18.82%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	5.43%	-28.27%	48.42%	30.89%	23.66%	47.56%	57.98%	49.74%	49.06%	81.18%
Debt to EBITDA	-0.97	-1.24	-1.19	-0.79	-3.27	-1.64	-1.99	-5.01	4.37	0.55
Net Debt to EBITDA	0.17	-0.30	0.05	-0.38	-2.24	-0.70	-1.00	-2.19	2.77	-0.15
Long-Term Debt to EBITDA	-0.97	-0.86	-1.19	-0.79	-3.27	-1.64	-1.99	-5.01	4.37	0.55
Debt to NOPAT	-1.32	-1.67	-1.56	-1.05	-2.91	-2.14	-2.50	-5.57	9.27	0.37
Net Debt to NOPAT	0.23	-0.41	0.06	-0.51	-1.99	-0.91	-1.25	-2.43	5.88	-0.10
Long-Term Debt to NOPAT	-1.32	-1.16	-1.56	-1.05	-2.91	-2.14	-2.50	-5.57	9.27	0.37
Altman Z-Score	-3.88	-6.35	-1.62	-4.03	-1.38	-1.43	-0.49	1.27	2.76	19.02
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.05	1.93	6.60	4.63	6.12	7.71	6.87	6.89	5.16	5.97
Quick Ratio	4.21	1.45	4.98	2.51	2.15	3.47	2.62	2.60	1.58	2.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-10	-14	-66	-45	-72	-91	-104	-54	9.90	116
Operating Cash Flow to CapEx	-59,135.52%	-24,886.22%	-1,392.65%	-2,990.97%	-1,998.87%	-801.62%	-831.69%	-427.78%	184.45%	1,442.65%
Free Cash Flow to Firm to Interest Expense	-4.01	-6.38	-14.62	-8.10	-3.78	-8.29	-7.94	-2.09	0.19	7.64
Operating Cash Flow to Interest Expense	-6.02	-8.16	-8.29	-11.35	-4.02	-9.28	-8.61	-2.29	0.17	7.82
Operating Cash Flow Less CapEx to Interest Expense	-6.03	-8.19	-8.89	-11.73	-4.22	-10.44	-9.64	-2.83	0.08	7.28
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.28	0.45	0.35	0.17	0.27	0.25	0.33	0.49	0.76	1.04
Accounts Receivable Turnover	10.97	10.98	9.29	6.44	12.07	5.05	3.87	6.99	12.03	11.02
Inventory Turnover	1.67	1.50	3.31	2.70	1.10	0.91	0.77	0.83	1.01	1.21
Fixed Asset Turnover	2.74	4.85	1.40	0.56	0.95	1.15	1.75	2.82	4.61	7.86
Accounts Payable Turnover	2.23	2.73	6.87	7.14	5.24	6.05	6.79	9.26	11.72	11.53
Days Sales Outstanding (DSO)	33.27	33.25	39.27	56.65	30.24	72.22	94.28	52.21	30.34	33.13
Days Inventory Outstanding (DIO)	218.19	242.90	110.44	135.14	331.15	400.78	471.89	442.37	362.46	302.67
Days Payable Outstanding (DPO)	163.69	133.49	53.10	51.13	69.64	60.29	53.77	39.41	31.15	31.65
Cash Conversion Cycle (CCC)	87.77	142.66	96.61	140.66	291.74	412.71	512.39	455.18	361.65	304.16
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1.69	0.46	39	41	84	130	192	219	224	327
Invested Capital Turnover	-5.14	-17.35	1.16	0.43	0.47	0.40	0.50	0.75	1.17	1.55
Increase / (Decrease) in Invested Capital	-0.59	2.15	38	2.54	43	46	63	27	5.24	103
Enterprise Value (EV)	84	71	81	132	295	226	327	831	1,110	4,032
Market Capitalization	86	66	83	111	237	184	276	763	1,021	4,054
Book Value per Share	$0.08	($0.35)	$1.56	$0.43	$0.44	$0.93	$0.72	$0.77	$0.60	$1.48
Tangible Book Value per Share	$0.08	($0.35)	$1.24	$0.26	$0.33	$0.87	$0.69	$0.75	$0.58	$1.46
Total Capital	15	16	83	64	111	186	244	306	276	430
Total Debt	14	20	43	44	85	97	102	154	140	81
Total Long-Term Debt	14	14	43	44	85	97	102	154	140	81
Net Debt	-2.51	4.92	-1.64	21	58	41	51	67	89	-22
Capital Expenditures (CapEx)	0.03	0.07	2.68	2.10	3.81	13	14	14	4.77	8.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.28	1.24	8.29	12	45	78	127	145	156	173
Debt-free Net Working Capital (DFNWC)	17	17	53	35	72	134	178	231	207	276
Net Working Capital (NWC)	17	10	53	35	72	134	178	231	207	276
Net Nonoperating Expense (NNE)	7.11	7.38	16	24	19	30	31	38	43	21
Net Nonoperating Obligations (NNO)	-2.51	4.92	-1.64	21	58	41	51	67	89	-22
Total Depreciation and Amortization (D&A)	0.74	1.00	3.33	4.41	4.30	5.58	7.25	9.37	11	8.85
Debt-free, Cash-free Net Working Capital to Revenue	3.90%	11.63%	36.44%	71.71%	153.46%	184.44%	157.22%	93.86%	60.36%	40.50%
Debt-free Net Working Capital to Revenue	238.09%	155.19%	232.43%	205.68%	244.62%	316.90%	220.34%	150.01%	80.25%	64.69%
Net Working Capital to Revenue	237.88%	97.87%	232.43%	205.50%	244.62%	316.90%	220.34%	150.01%	80.25%	64.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.73)	($1.61)	($1.91)	($1.45)	($0.89)	($0.88)	($0.51)	($0.33)	($0.13)	$0.85
Adjusted Weighted Average Basic Shares Outstanding	10.71M	12.89M	45.32M	46.35M	86.35M	121.28M	139.58M	197.87M	223.98M	233.08M
Adjusted Diluted Earnings per Share	($1.73)	($1.61)	($1.91)	($1.45)	($0.89)	($0.88)	($0.51)	($0.33)	($0.13)	$0.81
Adjusted Weighted Average Diluted Shares Outstanding	10.71M	12.89M	45.32M	46.35M	86.35M	121.28M	139.58M	197.87M	223.98M	243.34M
Adjusted Basic & Diluted Earnings per Share	($1.73)	($1.61)	($1.91)	($1.45)	($0.89)	($0.88)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	10.41M	12.15M	22.90M	45.19M	54.35M	86.15M	195.92M	222.16M	228.22M	237.62M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-12	-27	-42	-29	-45	-41	-28	15	97
Normalized NOPAT Margin	-151.30%	-113.79%	-118.30%	-248.46%	-98.80%	-107.63%	-50.48%	-17.88%	5.86%	22.81%
Pre Tax Income Margin	-250.36%	-183.05%	-192.26%	-387.06%	-164.50%	-179.41%	-88.52%	-42.77%	-10.94%	29.48%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.03	-7.74	-8.75	-10.94	-1.59	-5.92	-4.49	-1.54	0.42	9.15
NOPAT to Interest Expense	-4.24	-5.42	-6.12	-7.64	-1.53	-4.13	-3.13	-1.06	0.30	14.40
EBIT Less CapEx to Interest Expense	-6.04	-7.77	-9.34	-11.32	-1.79	-7.07	-5.52	-2.08	0.32	8.61
NOPAT Less CapEx to Interest Expense	-4.25	-5.45	-6.72	-8.02	-1.73	-5.29	-4.16	-1.60	0.20	13.86
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ADMA Biologics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	98.69%	89.45%	95.56%	77.33%	63.73%	47.86%	43.86%	78.29%	78.13%	59.06%
EBITDA Growth	48.04%	63.85%	112.81%	131.61%	273.60%	511.94%	1,366.08%	1,729.68%	268.81%	138.81%
EBIT Growth	35.32%	51.28%	94.39%	94.71%	191.57%	317.48%	2,693.57%	8,162.76%	363.49%	170.59%
NOPAT Growth	35.47%	54.07%	94.51%	94.84%	233.17%	334.93%	3,810.32%	10,688.33%	345.96%	1,139.90%
Net Income Growth	15.88%	26.54%	72.85%	53.72%	117.22%	-44.25%	362.28%	603.25%	1,299.96%	734.19%
EPS Growth	38.46%	28.57%	76.92%	57.14%	112.50%	-60.00%	366.67%	533.33%	1,400.00%	662.50%
Operating Cash Flow Growth	0.95%	77.95%	43.40%	52.78%	190.22%	338.47%	84.94%	853.36%	108.83%	185.37%
Free Cash Flow Firm Growth	-0.51%	57.21%	54.62%	59.94%	94.93%	115.33%	112.63%	231.69%	506.62%	344.24%
Invested Capital Growth	33.64%	13.81%	13.83%	10.40%	5.42%	2.39%	7.57%	2.34%	11.39%	45.73%
Revenue Q/Q Growth	21.19%	21.64%	13.87%	5.64%	11.90%	9.85%	10.79%	30.92%	11.80%	-1.91%
EBITDA Q/Q Growth	9.00%	37.06%	140.09%	37.63%	399.87%	49.35%	42.68%	71.76%	0.76%	-3.29%
EBIT Q/Q Growth	-1.44%	30.33%	87.07%	42.14%	1,857.20%	65.47%	54.16%	79.86%	1.01%	-3.40%
NOPAT Q/Q Growth	-1.55%	34.97%	86.58%	41.82%	2,723.07%	14.72%	111.94%	66.03%	10.48%	218.94%
Net Income Q/Q Growth	-8.24%	17.91%	44.50%	6.16%	140.26%	-787.88%	200.92%	80.06%	12.00%	211.61%
EPS Q/Q Growth	-14.29%	37.50%	40.00%	0.00%	133.33%	-900.00%	200.00%	62.50%	15.38%	200.00%
Operating Cash Flow Q/Q Growth	-3.54%	44.45%	-99.52%	58.85%	297.80%	46.83%	-112.61%	2,157.98%	-45.17%	100.64%
Free Cash Flow Firm Q/Q Growth	-9.35%	49.70%	7.02%	21.66%	86.16%	252.13%	-23.39%	716.60%	-57.28%	66.21%
Invested Capital Q/Q Growth	2.26%	0.69%	5.59%	1.54%	-2.35%	-2.20%	10.92%	-3.39%	6.28%	27.96%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	23.50%	28.36%	29.01%	27.76%	36.65%	42.06%	47.77%	53.60%	49.78%	53.88%
EBITDA Margin	-15.87%	-8.21%	2.89%	3.77%	16.82%	22.87%	29.46%	38.65%	34.83%	34.34%
Operating Margin	-22.67%	-12.12%	-1.43%	-0.79%	12.91%	19.26%	26.65%	36.57%	33.08%	32.60%
EBIT Margin	-22.70%	-13.00%	-1.48%	-0.81%	12.69%	19.12%	26.61%	36.56%	33.03%	32.53%
Profit (Net Income) Margin	-36.26%	-24.47%	-11.93%	-10.60%	3.81%	-23.87%	21.75%	29.91%	29.96%	95.19%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	96.77%	89.43%	97.71%	322.35%
Interest Burden Percent	159.76%	188.25%	808.21%	1,310.91%	30.04%	-124.86%	84.46%	91.49%	92.84%	90.78%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.23%	10.57%	2.29%	-222.35%
Return on Invested Capital (ROIC)	-10.89%	-6.36%	-0.84%	-0.51%	13.54%	15.71%	30.43%	45.47%	51.06%	162.67%
ROIC Less NNEP Spread (ROIC-NNEP)	-20.36%	-19.87%	-8.53%	-7.00%	7.26%	-19.68%	26.77%	41.19%	45.48%	127.82%
Return on Net Nonoperating Assets (RNNOA)	-17.74%	-8.02%	-5.06%	-4.99%	5.62%	-10.69%	16.15%	17.22%	12.02%	17.63%
Return on Equity (ROE)	-28.63%	-14.37%	-5.90%	-5.50%	19.16%	5.02%	46.58%	62.69%	63.08%	180.30%
Cash Return on Invested Capital (CROIC)	-45.92%	-26.32%	-21.11%	-15.10%	-4.86%	4.47%	5.62%	33.02%	36.64%	42.10%
Operating Return on Assets (OROA)	-10.99%	-6.41%	-0.83%	-0.53%	9.16%	14.57%	21.79%	33.56%	34.19%	33.92%
Return on Assets (ROA)	-17.55%	-12.07%	-6.69%	-6.89%	2.75%	-18.19%	17.81%	27.46%	31.02%	99.27%
Return on Common Equity (ROCE)	-28.63%	-14.37%	-5.90%	-5.50%	19.16%	5.02%	46.58%	62.69%	63.08%	180.30%
Return on Equity Simple (ROE_SIMPLE)	-70.05%	0.00%	-32.74%	-27.45%	-15.07%	0.00%	-2.37%	18.48%	29.38%	0.00%
Net Operating Profit after Tax (NOPAT)	-6.52	-4.24	-0.57	-0.33	8.69	9.96	21	35	39	124
NOPAT Margin	-15.87%	-8.48%	-1.00%	-0.55%	12.91%	13.48%	25.79%	32.71%	32.32%	105.09%
Net Nonoperating Expense Percent (NNEP)	9.46%	13.51%	7.69%	6.48%	6.28%	35.39%	3.67%	4.28%	5.57%	34.86%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.39%	-	-	-	3.62%	-	-	-	28.73%
Cost of Revenue to Revenue	76.50%	71.64%	70.99%	72.24%	63.35%	57.94%	52.23%	46.40%	50.22%	46.12%
SG&A Expenses to Revenue	43.20%	37.98%	28.63%	25.92%	22.58%	21.95%	20.33%	16.37%	16.34%	20.92%
R&D to Revenue	2.54%	2.15%	1.50%	2.33%	0.89%	0.60%	0.55%	0.52%	0.34%	0.33%
Operating Expenses to Revenue	46.18%	40.49%	30.44%	28.55%	23.74%	22.80%	21.11%	17.03%	16.71%	21.28%
Earnings before Interest and Taxes (EBIT)	-9.33	-6.50	-0.84	-0.49	8.54	14	22	39	40	38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.52	-4.10	1.65	2.26	11	17	24	41	42	40
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.75	5.02	5.05	5.59	5.32	7.55	9.70	13.77	20.09	11.62
Price to Tangible Book Value (P/TBV)	4.99	5.18	5.20	5.75	5.46	7.79	9.95	14.07	20.45	11.75
Price to Revenue (P/Rev)	3.66	4.96	4.04	3.94	3.44	3.96	5.27	7.85	12.17	9.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	74.50	68.39	20.51
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.34%	1.46%	4.88%
Enterprise Value to Invested Capital (EV/IC)	2.73	3.79	3.55	3.87	3.85	4.95	6.38	11.00	18.34	12.34
Enterprise Value to Revenue (EV/Rev)	4.55	5.39	4.51	4.36	3.77	4.30	5.60	8.01	12.23	9.45
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	79.39	34.56	29.05	28.20	37.71	27.31
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	1,232.41	52.02	36.08	31.61	40.83	29.05
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	940.99	73.33	51.20	31.49	40.76	18.45
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	126.18	74.46	36.21	54.42	33.97
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	112.11	117.59	33.70	52.74	34.76
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.51	1.01	1.06	1.03	1.00	1.04	0.91	0.75	0.48	0.23
Long-Term Debt to Equity	1.51	1.01	1.06	1.03	1.00	1.04	0.91	0.75	0.48	0.23
Financial Leverage	0.87	0.40	0.59	0.71	0.77	0.54	0.60	0.42	0.26	0.14
Leverage Ratio	2.65	2.13	2.38	2.45	2.58	2.36	2.31	2.15	1.93	1.69
Compound Leverage Factor	4.24	4.01	19.24	32.12	0.77	-2.95	1.95	1.96	1.79	1.53
Debt to Total Capital	60.23%	50.26%	51.52%	50.63%	50.09%	50.94%	47.73%	42.69%	32.21%	18.82%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	60.23%	50.26%	51.52%	50.63%	50.09%	50.94%	47.73%	42.69%	32.21%	18.82%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	39.77%	49.74%	48.48%	49.37%	49.91%	49.06%	52.27%	57.31%	67.79%	81.18%
Debt to EBITDA	-4.01	-5.01	-9.59	-22.42	13.66	4.37	2.57	1.50	0.89	0.55
Net Debt to EBITDA	-3.09	-2.19	-5.30	-13.11	7.00	2.77	1.74	0.55	0.19	-0.15
Long-Term Debt to EBITDA	-4.01	-5.01	-9.59	-22.42	13.66	4.37	2.57	1.50	0.89	0.55
Debt to NOPAT	-4.67	-5.57	-8.72	-12.91	161.97	9.27	4.53	1.67	0.96	0.37
Net Debt to NOPAT	-3.60	-2.43	-4.82	-7.55	82.95	5.88	3.07	0.62	0.20	-0.10
Long-Term Debt to NOPAT	-4.67	-5.57	-8.72	-12.91	161.97	9.27	4.53	1.67	0.96	0.37
Altman Z-Score	0.31	1.59	1.60	1.89	2.03	2.69	4.37	8.62	18.26	18.34
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.04	6.89	7.19	6.35	6.54	5.16	5.21	6.87	7.09	5.97
Quick Ratio	1.26	2.60	2.61	2.37	2.52	1.58	1.79	2.68	3.05	2.76
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-61	-31	-29	-22	-3.11	4.73	3.62	30	13	21
Operating Cash Flow to CapEx	-392.98%	-196.86%	-756.97%	-694.84%	1,583.22%	1,470.09%	-94.50%	2,209.39%	2,370.08%	1,821.40%
Free Cash Flow to Firm to Interest Expense	-10.98	-5.37	-4.69	-3.56	-0.49	0.15	0.96	7.81	3.61	5.09
Operating Cash Flow to Interest Expense	-2.38	-1.29	-2.41	-0.96	1.87	0.54	-0.59	12.07	7.15	12.18
Operating Cash Flow Less CapEx to Interest Expense	-2.99	-1.94	-2.73	-1.10	1.75	0.51	-1.21	11.52	6.85	11.51
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.49	0.56	0.65	0.72	0.76	0.82	0.92	1.04	1.04
Accounts Receivable Turnover	6.32	6.99	6.98	7.48	8.97	12.03	7.44	9.88	9.40	11.02
Inventory Turnover	0.76	0.83	0.88	0.98	1.00	1.01	1.00	1.04	1.17	1.21
Fixed Asset Turnover	2.48	2.82	3.29	3.74	4.19	4.61	5.03	5.97	7.06	7.86
Accounts Payable Turnover	4.99	9.26	9.88	12.87	9.00	11.72	11.39	13.55	14.55	11.53
Days Sales Outstanding (DSO)	57.76	52.21	52.32	48.77	40.68	30.34	49.07	36.94	38.83	33.13
Days Inventory Outstanding (DIO)	477.50	442.37	413.54	371.90	366.70	362.46	363.34	350.34	312.64	302.67
Days Payable Outstanding (DPO)	73.22	39.41	36.93	28.36	40.55	31.15	32.05	26.94	25.08	31.65
Cash Conversion Cycle (CCC)	462.04	455.18	428.93	392.32	366.83	361.65	380.36	360.34	326.39	304.16
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	217	219	231	235	229	224	249	240	255	327
Invested Capital Turnover	0.69	0.75	0.84	0.93	1.05	1.17	1.18	1.39	1.58	1.55
Increase / (Decrease) in Invested Capital	55	27	28	22	12	5.24	17	5.50	26	103
Enterprise Value (EV)	594	831	821	908	883	1,110	1,586	2,644	4,683	4,032
Market Capitalization	477	763	735	820	805	1,021	1,491	2,592	4,659	4,054
Book Value per Share	$0.51	$0.77	$0.66	$0.66	$0.67	$0.60	$0.67	$0.81	$0.99	$1.48
Tangible Book Value per Share	$0.49	$0.75	$0.64	$0.64	$0.66	$0.58	$0.65	$0.79	$0.98	$1.46
Total Capital	252	306	300	297	303	276	294	329	342	430
Total Debt	152	154	155	151	152	140	140	140	110	81
Total Long-Term Debt	152	154	155	151	152	140	140	140	110	81
Net Debt	117	67	86	88	78	89	95	52	23	-22
Capital Expenditures (CapEx)	3.38	3.75	1.95	0.87	0.76	1.20	2.35	2.07	1.06	2.76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	145	145	158	162	158	156	178	171	187	173
Debt-free Net Working Capital (DFNWC)	180	231	227	224	232	207	223	260	273	276
Net Working Capital (NWC)	180	231	227	224	232	207	223	260	273	276
Net Nonoperating Expense (NNE)	8.38	7.99	6.22	6.04	6.12	28	3.31	3.00	2.82	12
Net Nonoperating Obligations (NNO)	117	67	86	88	78	89	95	52	23	-22
Total Depreciation and Amortization (D&A)	2.81	2.39	2.49	2.75	2.78	2.77	2.33	2.24	2.16	2.13
Debt-free, Cash-free Net Working Capital to Revenue	110.93%	93.86%	86.95%	77.74%	67.31%	60.36%	62.86%	51.86%	48.74%	40.50%
Debt-free Net Working Capital to Revenue	137.69%	150.01%	125.00%	107.78%	98.96%	80.25%	78.87%	78.58%	71.39%	64.69%
Net Working Capital to Revenue	137.69%	150.01%	125.00%	107.78%	98.96%	80.25%	78.87%	78.58%	71.39%	64.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.08)	($0.05)	($0.03)	($0.03)	$0.01	($0.08)	$0.08	$0.14	$0.15	$0.48
Adjusted Weighted Average Basic Shares Outstanding	196.38M	197.87M	221.92M	222.68M	225.28M	223.98M	228.87M	232.42M	234.57M	233.08M
Adjusted Diluted Earnings per Share	($0.08)	($0.05)	($0.03)	($0.03)	$0.01	($0.08)	$0.08	$0.13	$0.15	$0.45
Adjusted Weighted Average Diluted Shares Outstanding	196.38M	197.87M	221.92M	222.68M	233.76M	223.98M	236.41M	242.17M	244.80M	243.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	196.78M	222.16M	222.27M	224.91M	225.97M	228.22M	231.81M	233.08M	236.39M	237.62M
Normalized Net Operating Profit after Tax (NOPAT)	-6.52	-4.24	-0.57	-0.33	6.08	9.96	21	35	39	27
Normalized NOPAT Margin	-15.87%	-8.48%	-1.00%	-0.55%	9.04%	13.48%	25.79%	32.71%	32.32%	22.82%
Pre Tax Income Margin	-36.26%	-24.47%	-11.93%	-10.60%	3.81%	-23.87%	22.47%	33.45%	30.67%	29.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.67	-1.13	-0.14	-0.08	1.33	0.44	5.78	10.36	11.31	9.28
NOPAT to Interest Expense	-1.17	-0.74	-0.09	-0.05	1.36	0.31	5.60	9.27	11.07	29.97
EBIT Less CapEx to Interest Expense	-2.28	-1.79	-0.46	-0.22	1.22	0.40	5.16	9.81	11.01	8.61
NOPAT Less CapEx to Interest Expense	-1.77	-1.39	-0.41	-0.19	1.24	0.27	4.98	8.72	10.77	29.30
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About ADMA Biologics' Financials

When does ADMA Biologics's financial year end?

According to the most recent income statement we have on file, ADMA Biologics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has ADMA Biologics' net income changed over the last 9 years?

ADMA Biologics' net income appears to be on a downward trend, with a most recent value of $197.67 million in 2024, falling from -$17.97 million in 2015. The previous period was -$28.24 million in 2023.

What is ADMA Biologics's operating income?

ADMA Biologics's total operating income in 2024 was $138.98 million, based on the following breakdown:

Total Gross Profit: $219.55 million
Total Operating Expenses: $80.57 million

How has ADMA Biologics revenue changed over the last 9 years?

Over the last 9 years, ADMA Biologics' total revenue changed from $7.18 million in 2015 to $426.45 million in 2024, a change of 5,841.4%.

How much debt does ADMA Biologics have?

ADMA Biologics' total liabilities were at $139.66 million at the end of 2024, a 28.0% decrease from 2023, and a 510.0% increase since 2015.

How much cash does ADMA Biologics have?

In the past 9 years, ADMA Biologics' cash and equivalents has ranged from $9.91 million in 2016 to $103.15 million in 2024, and is currently $103.15 million as of their latest financial filing in 2024.

How has ADMA Biologics' book value per share changed over the last 9 years?

Over the last 9 years, ADMA Biologics' book value per share changed from 0.08 in 2015 to 1.48 in 2024, a change of 1,827.4%.

Remove Ads

Related Companies

This page (NASDAQ:ADMA) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Financials

Frequently Asked Questions About ADMA Biologics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Financials

Annual Income Statements for ADMA Biologics

Quarterly Income Statements for ADMA Biologics

Annual Cash Flow Statements for ADMA Biologics

Quarterly Cash Flow Statements for ADMA Biologics

Annual Balance Sheets for ADMA Biologics

Quarterly Balance Sheets for ADMA Biologics

Annual Metrics and Ratios for ADMA Biologics

Quarterly Metrics and Ratios for ADMA Biologics

Frequently Asked Questions About ADMA Biologics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools